Breakeven Is Near for Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)

We feel now is a pretty good time to analyse Oncodesign Precision Medicine Société anonyme's (EPA:ALOPM) business as it appears the company may be on the cusp of a considerable accomplishment. Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. On 31 December 2024, the €8.6m market-cap company posted a loss of €7.2m for its most recent financial year. As path to profitability is the topic on Oncodesign Precision Medicine Société anonyme's investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Oncodesign Precision Medicine Société anonyme is bordering on breakeven, according to some French Biotechs analysts. They anticipate the company to incur a final loss in 2024, before generating positive profits of €200k in 2025. So, the company is predicted to breakeven approximately a year from now or less! How fast will the company have to grow to reach the consensus forecasts that anticipate breakeven by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 55% year-on-year, on average, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

We're not going to go through company-specific developments for Oncodesign Precision Medicine Société anonyme given that this is a high-level summary, but, keep in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Check out our latest analysis for Oncodesign Precision Medicine Société anonyme

One thing we would like to bring into light with Oncodesign Precision Medicine Société anonyme is it currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

There are too many aspects of Oncodesign Precision Medicine Société anonyme to cover in one brief article, but the key fundamentals for the company can all be found in one place – Oncodesign Precision Medicine Société anonyme's company page on Simply Wall St. We've also compiled a list of important aspects you should further examine:

1. Valuation: What is Oncodesign Precision Medicine Société anonyme worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Oncodesign Precision Medicine Société anonyme is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Oncodesign Precision Medicine Société anonyme’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.